Exelixis, Inc. - Common Stock (NQ:EXEL)

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.

Looking for growth without the hefty price tag? Consider NASDAQ:EXEL. ↗

November 06, 2023

Via Chartmill

Where Exelixis Stands With Analysts ↗

November 02, 2023

Via Benzinga

Exelixis (EXEL) Q3 2023 Earnings Call Transcript ↗

November 02, 2023

EXEL earnings call for the period ending September 30, 2023.

Topics Earnings

Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 01, 2023

There is one key reason to consider the stock.

Earnings Outlook For Exelixis ↗

October 31, 2023

Via Benzinga

Is Exelixis Stock a Buy Now? ↗

October 18, 2023

4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

October 28, 2023

Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Topics Stocks

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

Via FinancialNewsMedia

Why Exelixis Stock Is Trading Lower Today ↗

October 23, 2023

Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in

Via Benzinga

14 Analysts Have This to Say About Exelixis ↗

October 11, 2023

Via Benzinga

2 Top Biotech Stocks Defying the Bear Market ↗

September 15, 2023

The best may be yet to come for these companies.

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

The Latest Analyst Ratings for Exelixis ↗

September 13, 2023

Via Benzinga

October 22, 2023

These three lesser-known biotech companies are profitable and growing revenue.

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

October 19, 2023

Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023

October 18, 2023

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗

October 13, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.

Via Chartmill

Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains ↗

October 02, 2023

Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023 ↗

September 26, 2023

Via Benzinga

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 20, 2023

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy ↗

September 16, 2023

Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...

Via Talk Markets

4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 16, 2023

A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

Topics Stocks

September 12, 2023

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

August 31, 2023

From Exelixis

Both stocks have outperformed the broader market in the last 12 months.

The Top Healthcare Stocks to Buy With $100 ↗

August 30, 2023

Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest ↗

Exelixis Inc. (NASDAQ: EXEL) Sets New 52-Week High in Tuesday Session

August 29, 2023

Via Investor Brand Network

August 24, 2023

Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the...

Via Benzinga

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 24, 2023